The cardiovascular benefits of statin therapy are well documented; however, no trial has identified a target level for LDL cholesterol below which no further benefit of treatment is seen. With the introduction of more-aggressive optional LDL-cholesterol targets in US guidelines, Antonio Gotto and John Farmer consider the rationale for combination therapy of statins with the cholesterol absorption inhibitor ezetimibe.
- Antonio M Gotto Jr
- John A Farmer